Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
02 nov 2007 - 08:01
Statutaire naam
Crucell N.V.
Titel
DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.
Bericht
Sittard/Leiden, The Netherlands, November 2, 2007 – DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.
Gerelateerde downloads
Datum laatste update: 01 september 2024